GlassScriptPhysician profile
Andrew M Abreo
NPI 1447518246
$6,500.64
in general payments reported to CMS, 2019-2025
14 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $50.73 · 2021: $53.63 · 2022: $136 · 2023: $2,451 · 2024: $3,072 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,928 · Honoraria: $2,025 · Food and Beverage: $1,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,928.00 |
| Honoraria | $2,025.00 |
| Food and Beverage | $1,004.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $2,928.00 | 2024 | Dupixent |
| Horizon Therapeutics Plc | $2,060.98 | 2023 | Actimmune |
| Astrazeneca Pharmaceuticals LP | $389.76 | 2019-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $274.42 | 2021-2024 | Takhzyro, Eohilia, Cuvitru |
| Genzyme Corporation | $263.79 | 2019-2025 | |
| Amgen INC. | $157.65 | 2024-2025 | Actimmune |
| Csl Behring | $123.59 | 2019-2020 | |
| Pharming Healthcare, INC. | $104.05 | 2025 | Joenja |
| Grifols Shared Services North America, INC. | $96.93 | 2023 | Xembify |
| Pfizer INC. | $35.37 | 2025 | |
| Shire North American Group INC | $18.43 | 2019 | |
| Kaleo, INC. | $17.80 | 2019 | |
| Glaxosmithkline, LLC. | $17.05 | 2020 | |
| Alk-Abello, INC | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Abreo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.